X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Tom Wilbur

Tom Wilbur is Director of Public Affairs at PhRMA focusing on message development and opinion research. Prior to joining PhRMA in 2019, Tom worked on Capitol Hill and on political campaigns for nearly a decade, most recently responsible for communications, campaigns and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the virtual office enjoys reading, running, hiking, golfing, and spending time with friends and family.

Recent Posts

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

By Tom Wilbur  |    July 2, 2021
As we head into the Fourth of July weekend, Americans are reemerging from the COVID-19 pandemic with heightened hopes and confidence in a strong U.S. recovery. The COVID-19 vaccines have been...   Read More

Four solutions Americans support to make health care more affordable

By Tom Wilbur  |    May 13, 2021
Health care costs and affordability remain a major challenge for most Americans, even among those with insurance. According to a March Gallup poll, nearly one-in-five (18%) U.S. adults report that...   Read More

ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy

By Tom Wilbur  |    March 11, 2021
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would...   Read More

Key excerpts: PhRMA submits comments to keep the six protected classes protected

By Tom Wilbur  |    February 19, 2021
Earlier this month, PhRMA submitted comments to CMS regarding the Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This RFA was released on January 19,...   Read More

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

By Tom Wilbur  |    February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...   Read More

Action needed to preserve the six protected classes

By Tom Wilbur  |    February 3, 2021
In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing...   Read More

Key facts: The final rebate rule will be a positive change for patients

By Tom Wilbur  |    January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...   Read More

End of year Part D reading List

By Tom Wilbur  |    December 18, 2020
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Insights from the election: Meeting voters where they are on health care

By Tom Wilbur  |    December 15, 2020
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates